New drug vs chemo for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called IBI354 against standard chemotherapy for people with ovarian, primary peritoneal, or fallopian tube cancer that stopped responding to platinum-based treatments. It aims to see if the new drug works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have advanced ovarian, primary peritoneal, or fallopian tube cancer that cannot be removed by surgery or has spread.
- Your cancer got worse during or after your most recent treatment.
- You have at least one tumor that can be measured by a scan.
- You have not had certain chemotherapy drugs before that are used in the control group (paclitaxel, gemcitabine, liposomal doxorubicin, or topotecan).
- You must have good organ function and a heart pumping ability of at least 50%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This trial tests a new drug called JSKN003 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if this drug can shrink tumors or slow cancer growth. If you qualify, you may receive this experimental treatment and be closely monitored by a study team.
This trial tests a new drug called BL-M07D1 against standard chemotherapy for people with HER2-positive ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. It aims to find out if BL-M07D1 works better than the doctor's choice of chemo.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This trial tests a new drug called SYS6043 (which targets a protein called B7-H3 found on some cancer cells) for people with advanced ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum chemotherapy. It compares SYS6043 to standard treatments like paclitaxel or topotecan, and aims to see if it can shrink tumors or slow the cancer.
Hear when a new Primary Peritoneal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.